Lung cancer microbiome study
Part of Cancer, Infections, Lungs & breathing clinical trials.
This study looks at the bacteria and other microbes in lung cancer tissue to understand how they might affect the disease. It may help find new ways to treat or manage non-small cell lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-small cell lung cancer (a common type of lung cancer).
- You are between 30 and 80 years old.
- You have not had chemotherapy, radiation, targeted therapy, or immunotherapy before surgery.
- You do not have another type of cancer or a recurrence of lung cancer.
- You do not have a weakened immune system or certain lung conditions like active tuberculosis or bronchiectasis with infection.
- You have not recently taken antifungal medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether microplastics (tiny plastic particles) are present in human lung tissue. Researchers will examine lung samples from people having surgery for various lung conditions to learn more about the potential impact of these particles.
This study looks at how the bacteria in your gut (microbiome) might affect how well your lung cancer treatment works and what side effects you experience. The goal is to learn if certain gut bacteria can predict treatment response or side effects for people with advanced non-small cell lung cancer.
This study tests whether giving a combination of chemotherapy and immunotherapy before surgery can improve outcomes for people with non-small cell lung cancer. Researchers are also studying how the bacteria in your gut (microbiome) affect how well the treatment works. This approach may shrink the tumor and make it easier to remove surgically.
This trial studies how gut bacteria (the microbiome) and the body’s immune signs change over time while you receive PD-1–based immunotherapy for advanced, unresectable non–small cell lung cancer. The goal is to learn which immune and microbial patterns might relate to how well treatment works and how patients respond.
This trial collects tissue samples from your lung tumor and any tumors that have spread to other parts of your body. They will study the genetic makeup of these samples to better understand lung cancer and improve future treatments.
This study looks at how the bacteria in your gut might affect how well immunotherapy works for certain cancers. It is for people with advanced lung cancer, melanoma, or certain gynecologic cancers who are about to start immunotherapy, and it may help doctors understand why some people respond better than others.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.